Two key, recent events finally gave Rivian (NASDAQ:RIVN) stock a significantly larger portion of the respect that it deserves. Analysts are starting to talk positively about the electric vehicle (EV) manufacturer and new partnerships are looking possible. Moreover, the automaker reiterated last month it believes it can generate positive gross margins in the fourth quarter.
0 Comments
Intel’s (NASDAQ:INTC) management is confident, but should investors be confident about Intel? CEO Pat Gelsinger sees “steady progress” but your financial decisions should be based on facts, not rhetoric. After mulling over the relevant facts and circumstances, we’re assigning Intel stock a “D” grade and we’re not eager to recommend it now. Even after a share-price
0 Comments
Hyper-growth stocks offer excitement, but their lifespan can be fleeting. Successful growth investors seek durable companies with long-term potential. Innovative firms continually emerge, offering transformative growth opportunities.  Despite misconceptions, the U.S. economy exhibits promise. GDP grows steadily, and unemployment recently hit historic lows near 4% as reduced inflation stabilizes prices, easing financial strain. Wage hikes
0 Comments
In the last week of May, SaaS stocks faced a reckoning. A revenue miss by Salesforce (NYSE:CRM) triggered one of the sector’s severest selloffs in two years. However, investors have been throwing out the baby with the bath water, creating some attractive SaaS stocks to buy. In hindsight, the selloff in SaaS was slowly brewing
0 Comments
The biotech sector, under the life sciences umbrella, exited 2023 with 41 bankruptcies. This was not surprising given the disparity between biotech’s high-capital requirements and rising interest rates set by the Fed. Despite these challenges, some of the best biotech stocks show promise and resilience in a volatile market environment. At the same time, smaller
0 Comments